Eptinezumab (formerly known as ALD403) is our pivotal-stage monoclonal antibody that binds potently and selectively to inhibit calcitonin gene-related peptide (CGRP), a protein known to play a key role in migraine disease and progression. Eptinezumab the only investigational anti-CGRP therapy designed to be administered by quarterly infusion to allow for 100% of the dose available to inhibit CGRP.1
Eptinezumab is currently in multiple global, randomized pivotal, Phase 3 studies to assess its efficacy and safety in migraine prevention.
- PROMISE 1 Phase 3 study in frequent episodic migraine ongoing. Click here to view the press release and here to view the presentation announcing top-line results
- PROMISE 2 Phase 3 study in chronic migraine ongoing.
- Open-label safety study ongoing.
1 Baker B, Schaeffler B, Cady R, et al; Rational design of a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, ALD403 (eptinezumab), intended for the prevention of migraine. Poster presented at the American Academy of Neurology (AAN) 2017 Annual Meeting.